首页 › 基金 › ORBIMED ADVISORS LLC › NKTR
ORBIMED ADVISORS LLC 对 NKTR 的持仓历史
NEKTAR THERAPEUTICS · 医疗保健
ORBIMED ADVISORS LLC 在 Q2 2026 的 13F 申报中披露持有 NKTR(NEKTAR THERAPEUTICS)465,346 股,市值约 US$32.5M,约占其申报组合的 0.65%,在其申报持仓中市值排名第 42 位。 ORBIMED ADVISORS LLC 最近 2 个申报季度中有 2 个季度披露了 NKTR 持仓,最早可追溯至 Q1 2026。
最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR
ORBIMED ADVISORS LLC 对 NKTR 的持仓演变
ORBIMED ADVISORS LLC 于 Q1 2026 首次披露 NKTR 持仓:275,000 股(约 US$19.8M)。 该持仓在 Q2 2026 达到峰值 465,346 股,市值约 US$32.5M。 在 2 次申报中,ORBIMED ADVISORS LLC 1 次增持、0 次减持、0 次保持不变。 最近一期申报(Q2 2026)显示持股 465,346 股、市值约 US$32.5M,环比增持 190,346 股。。 持仓曾出现大幅变动:Q2 2026 增持约 69% (随后一个季度股价下跌 13%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q1 2026 | 275.00K | $19.79M | 新进 |
| Q2 2026 | 465.35K | $32.49M | 增持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 NKTR 与 13F 数据
NKTR(NEKTAR THERAPEUTICS)属于医疗保健行业。我们追踪的基金中还有 70 只申报持有 NKTR,申报仓位最大的包括:Two Seas Capital LP (US$202.6M), BVF INC/IL (US$166.9M), Vestal Point Capital, LP (US$69.8M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 NKTR 的基金
- Two Seas Capital LP 3.35M 股 · $202.58M · Q3 2026
- BVF INC/IL 2.39M 股 · $166.92M · Q2 2026
- Vestal Point Capital, LP 1.00M 股 · $69.81M · Q2 2026
- Prosight Management, LP 810.00K 股 · $56.55M · Q2 2026
- ARMISTICE CAPITAL, LLC 724.00K 股 · $50.54M · Q2 2026
- BRAIDWELL LP 473.62K 股 · $33.06M · Q2 2026
- Sofinnova Investments, Inc. 471.76K 股 · $32.93M · Q2 2026
- DAFNA Capital Management LLC 318.38K 股 · $22.23M · Q2 2026
- 22NW, LP 281.12K 股 · $19.62M · Q2 2026
- ADAR1 Capital Management, LLC 244.18K 股 · $17.05M · Q2 2026
- Creek Drive Management Group LLC 243.00K 股 · $16.96M · Q2 2026
- SEVEN GRAND MANAGERS, LLC 240.00K 股 · $16.75M · Q2 2026
更多关于 ORBIMED ADVISORS LLC
常见问题
How long has ORBIMED ADVISORS LLC held NKTR?
ORBIMED ADVISORS LLC has disclosed NKTR holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is ORBIMED ADVISORS LLC's current position in NKTR?
As of Q2 2026, ORBIMED ADVISORS LLC holds 465.35K shares of NKTR (NEKTAR THERAPEUTICS), valued at $32.49M, representing 0.65% of its reported portfolio and ranking #42.
Has ORBIMED ADVISORS LLC been buying or selling NKTR?
In the latest 13F filing (Q2 2026), ORBIMED ADVISORS LLC increased its position in NKTR. The position peaked in Q2 2026 at 465.35K shares.
Which other funds hold NKTR?
Other major institutional holders of NKTR include Two Seas Capital LP, BVF INC/IL, Vestal Point Capital, LP, among 70 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.